Insider Selling: Aveanna Healthcare (NASDAQ:AVAH) CEO Sells 90,000 Shares of Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CEO Jeff Shaner sold 90,000 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $1,035,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,561,972 shares of the company’s stock, valued at $29,462,678. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Aveanna Healthcare Price Performance

NASDAQ AVAH traded up $0.54 during trading on Monday, reaching $13.70. 5,364,375 shares of the company traded hands, compared to its average volume of 1,804,109. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16. The stock’s 50 day moving average price is $9.58 and its two-hundred day moving average price is $7.92. The company has a market cap of $2.99 billion, a price-to-earnings ratio of 11.14, a P/E/G ratio of 0.92 and a beta of 1.90. Aveanna Healthcare Holdings Inc. has a 1-year low of $5.93 and a 1-year high of $13.98.

Aveanna Healthcare (NASDAQ:AVAH) last issued its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%.The business had revenue of $670.48 million during the quarter, compared to analysts’ expectations of $638.61 million. As a group, analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AVAH. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. Royal Bank Of Canada upped their target price on shares of Aveanna Healthcare from $10.00 to $16.00 and gave the stock an “outperform” rating in a report on Monday. Barclays increased their target price on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. BMO Capital Markets lifted their price target on shares of Aveanna Healthcare from $10.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Finally, Truist Financial boosted their price target on shares of Aveanna Healthcare from $11.00 to $15.00 and gave the company a “hold” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.89.

Hedge Funds Weigh In On Aveanna Healthcare

Institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC raised its position in Aveanna Healthcare by 21.2% in the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after purchasing an additional 4,602 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Aveanna Healthcare by 8.3% during the first quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after purchasing an additional 25,974 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Aveanna Healthcare by 522.0% in the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after buying an additional 63,010 shares in the last quarter. Creative Planning increased its stake in shares of Aveanna Healthcare by 15.1% in the second quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after buying an additional 6,171 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Aveanna Healthcare by 65.0% in the second quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after buying an additional 62,348 shares during the last quarter. Institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.